A 32-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and night sweats. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli (AFB). He is started on standard anti-tuberculous therapy (ATT) with isoniazid, rifampicin, pyrazinamide, and ethambutol. After 2 weeks of therapy, he develops sudden-onset jaundice, dark urine, and abdominal discomfort. Liver function tests show ALT 320 U/L, AST 380 U/L, and total bilirubin 4.2 mg/dL. What is the most appropriate next step in management?

Explanation

## Drug-Induced Hepatotoxicity in TB Treatment ### Clinical Scenario Analysis This patient has developed **drug-induced liver injury (DILI)** during the intensive phase of ATT. He presents with symptomatic jaundice, dark urine, and abdominal discomfort with ALT 320 U/L (~8× ULN), AST 380 U/L (~9.5× ULN), and total bilirubin 4.2 mg/dL — a severe hepatotoxicity pattern requiring immediate action. ### Identifying the Hepatotoxic Drugs The three hepatotoxic drugs in the standard HRZE regimen are: - **Isoniazid (INH)** — causes hepatocellular injury; risk ~1–2% - **Rifampicin (RIF)** — causes cholestatic and hepatocellular injury - **Pyrazinamide (PZA)** — most hepatotoxic of the three; dose-dependent injury **Ethambutol** is NOT hepatotoxic and can be safely continued. ### WHO / RNTCP Guidelines for ATT-Induced Hepatotoxicity **Key Point:** Per WHO 2010 guidelines and the Revised National TB Control Programme (RNTCP) / National TB Elimination Programme (NTEP) India guidelines, when a patient develops **symptomatic hepatitis with jaundice** or transaminases **>3× ULN with symptoms** (or >5× ULN without symptoms), the correct management is: 1. **Stop ALL three hepatotoxic drugs immediately** (INH, RIF, PZA) 2. **Continue ethambutol** (± a fluoroquinolone or streptomycin as a bridging regimen to maintain anti-TB coverage) 3. **Monitor LFTs** until bilirubin and transaminases normalize (typically 2–4 weeks) 4. **Restart drugs sequentially** once LFTs normalize: **Rifampicin first → Isoniazid → Pyrazinamide** (PZA is often omitted if the intensive phase is extended) This patient has symptomatic jaundice with bilirubin 4.2 mg/dL and transaminases ~8–9× ULN — this clearly mandates stopping ALL hepatotoxic drugs. ### Why Option C is Correct Option C — **"Stop all four drugs immediately; restart with isoniazid and rifampicin only after liver function normalizes"** — most closely aligns with standard guidelines. Stopping all four drugs removes the offending agents promptly. Restarting with INH and RIF (the two most potent bactericidal agents) after normalization is consistent with WHO/RNTCP re-challenge protocols, where PZA is often not reintroduced if the intensive phase is extended. **Clinical Pearl (Harrison's Principles of Internal Medicine, 21st ed.):** In ATT-induced hepatotoxicity with jaundice, all potentially hepatotoxic drugs must be stopped. Re-challenge is performed sequentially after LFT normalization, prioritizing rifampicin and isoniazid. ### Why Not the Other Options? | Option | Rationale | |--------|-----------| | A — Continue with hepatoprotective agents | Silymarin and UDCA have NO evidence base in ATT-DILI; continuing hepatotoxic drugs risks acute liver failure — **dangerous** | | B — Stop only PZA and ETH; continue INH + RIF | INH and RIF are themselves hepatotoxic; continuing them in the setting of symptomatic jaundice and 8–9× ULN transaminases is **not guideline-compliant** and risks worsening liver injury | | D — Switch to second-line drugs immediately | Second-line drugs (fluoroquinolones, injectables, bedaquiline) are reserved for **drug-resistant TB (MDR/XDR-TB)**; this patient has drug-susceptible TB — **inappropriate** | ### Monitoring During Restart - Recheck LFTs every 1–2 weeks during drug-free period - Restart RIF first; if tolerated for 1 week, add INH; monitor LFTs weekly - If PZA is reintroduced and hepatotoxicity recurs, permanently omit PZA and extend the intensive phase - Ensure adequate nutrition; counsel on alcohol abstinence [cite: WHO Treatment of Drug-Susceptible Tuberculosis 2022; NTEP India Guidelines 2020; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Tuberculosis]